OGT launches CytoCell FISH probes for glial tumors

Oxford, UK – 04 May 2016. OGT, The Molecular Genetics Company, has launched its CE-IVD labeled CytoCell^® 1p36/1q25 and 19q13/19p13 Deletion Probe Kit*, a cost-effective fluorescence in situ hybridization (FISH) kit for the reliable investigation of glial tumors.  

Co-deletion of the 1p36.32 and 19q13.33 regions are frequently reported in many classes of gliomas.^1,2 Moreover, the presence of a 1p and 19q co-deletion is a strong prognostic factor, which is often associated with improved outcome and responsiveness to therapy in stage II and stage III gliomas.³ Presenting the gold standard of co-deletion detection, FISH is also central in the move towards replacing morphological grading with molecular analysis — providing the molecular insights to overcome the variable relationship between histological type and clinical outcome.

Created specifically for the investigation of co-deletion status in glial tumor specimens, the new CE-IVD labelled CytoCell 1p36/1q25 and 19q13/19p13 Deletion Probe Kit consistently delivers bright, specific signals with minimal background. By enabling clear and accurate scoring, the need for repeat testing is minimized, saving both time and resources. Ease of use has also been prioritized, with the convenience of ready-to-use pre-mixed probes saving aliquoting time, while also minimizing potential errors. The cost-effective, quality-assured kit brings confidence to glioma investigations, with optimization for FFPE samples enhanced when used alongside the CytoCell Tissue Pretreatment Kit.  

The Head of Cancer Cytogenetics at the Northern Genetics Service in Newcastle, Gavin Cuthbert FRCPath, who is currently in the process of completely transitioning to CytoCell probes, commented: “Accurately detecting co-deletion status is vital to our glioma investigations, and we have been consistently impressed with the quality and reproducibility of results using the new CytoCell kit — not to mention the support offered by OGT’s customer service. We now have a cost-effective test we can rely on, that is also easy to use and interpret.”

Senior Product Manager for Pathology at OGT, Steve Chatters explained: “More laboratories are realizing the importance of FISH-based co-deletion analysis for glioma investigations, and our new kit is set to further drive this trend. This builds upon OGT’s existing cancer FISH portfolio, providing confident diagnoses to aid in the fight against cancer.”

References

1. Vogazianou AP et al., Neuro Oncol. 2010;12(7):664-78.
2. Bromberg JEC et al., Oncol. 2009;14:155-163.
3. Jenkins RB et al., Cancer Res 2006;66(20):9852-61.

About OGT

OGT, a Sysmex Group company, is a leading global provider of clinical and diagnostic genomic solutions that are created for scientists by scientists - including CytoCell^®, CytoSure^® and SureSeq™ ranges of FISH, microarray and NGS products. The company is dedicated to creating products that enable researchers and clinical decision makers to reach the right care decisions for each patient, every time. OGT strives to unlock the future of genetic clinical care with a commitment to working in partnership with its customers - not only by sharing its expertise of 25 years at the forefront of genetic endeavour, but also by working closely with scientists to understand their unique challenges, and to customise its approach to meet their exact needs. Dedicated to improving clinical care, OGT believes that through partnership—together—we’ll achieve more.

For more information on the Company, please visit our website at ogt.com

CytoSure^®, SureSeq™ and myProbes^®: For Research Use Only, not for use in diagnostic procedures. CytoCell: Some products may not be available in your region.

About Sysmex Corporation

Sysmex Corporation is a world leader in clinical laboratory systemization and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Serving customers for more than 50 years, Sysmex focuses on technological leadership in diagnostic science and information tools that make a difference in the health of people worldwide. The company is also exploring emerging opportunities in the life science field. Its R&D efforts focus on the development of high-value-added testing and diagnostic technologies that are innovative, original and optimize individual health. Sysmex also seeks to leverage its state-of-the-art technologies for cell, gene and protein analysis. The company, headquartered in Kobe, Japan, has subsidiaries in North America, Latin America, Europe, the Middle East, Africa, China and Asia Pacific and employs more than 9,000 employees worldwide. Sysmex Corporation is listed in the top tier of the Tokyo Stock Exchange.

For more information about Sysmex Corporation and its affiliate companies, please visit www.sysmex.co.jp/en/.